Molecular alterations in primary prostate cancer after androgen ablation therapy. - Wikidata - wikimedia - TriplyDB

Molecular alterations in primary prostate cancer after androgen ablation therapy.

Molecular alterations in primary prostate cancer after androgen ablation therapy.

http://www.wikidata.org/entity/Q33224548

about

LNCaP Atlas: gene expression associated with in vivo progression to castration-recurrent prostate cancer The metalloproteinase ADAMTS1: a comprehensive review of its role in tumorigenic and metastatic pathways.Molecular pathways involved in prostate carcinogenesis: insights from public microarray datasets Structure of the large ribosomal subunit from human mitochondria.A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth Integrated analysis of gene expression and tumor nuclear image profiles associated with chemotherapy response in serous ovarian carcinoma Expression of GITR Enhances Multiple Myeloma Cell Sensitivity to Bortezomib Transcriptional signatures of Ral GTPase are associated with aggressive clinicopathologic characteristics in human cancer.Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis.Transcription factor and microRNA regulation in androgen-dependent and -independent prostate cancer cells.Quantitative RT-PCR gene expression analysis of laser microdissected tissue samples A stochastic model for identifying differential gene pair co-expression patterns in prostate cancer progression.The Ron receptor tyrosine kinase positively regulates angiogenic chemokine production in prostate cancer cells Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models.The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth.Epithelial-mesenchymal transition in prostate cancer: an overview.Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality.Genetic association analysis of the RTK/ERK pathway with aggressive prostate cancer highlights the potential role of CCND2 in disease progression Influence of hypoxia induced by minimally invasive prostatectomy on gene expression: implications for biomarker analysis.Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response.Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines Androgen depletion up-regulates cadherin-11 expression in prostate cancer.Comparative evaluation of set-level techniques in predictive classification of gene expression samples.DNA methylation profiles of airway epithelial cells and PBMCs from healthy, atopic and asthmatic children Genome-wide association study identifies a novel susceptibility locus at 12q23.1 for lung squamous cell carcinoma in han chinese Novel tumor suppressor function of glucocorticoid-induced TNF receptor GITR in multiple myeloma.The expression of SPARC in human tumors is consistent with its role during cell competition.Protein-network modeling of prostate cancer gene signatures reveals essential pathways in disease recurrence.Genome-wide linkage scan for prostate cancer susceptibility in Finland: evidence for a novel locus on 2q37.3 and confirmation of signal on 17q21-q22.Testosterone level in men with type 2 diabetes mellitus and related metabolic effects: A review of current evidence.PNAS-4, an Early DNA Damage Response Gene, Induces S Phase Arrest and Apoptosis by Activating Checkpoint Kinases in Lung Cancer Cells.The tumor suppressor ING1b is a novel corepressor for the androgen receptor and induces cellular senescence in prostate cancer cells.Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression.Molecular characterization of the Ggamma-globin-Tag transgenic mouse model of hormone refractory prostate cancer: comparison to human prostate cancer The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation.Molecular consequences of SOD2 expression in epigenetically silenced pancreatic carcinoma cell lines Screening key microRNAs for castration-resistant prostate cancer based on miRNA/mRNA functional synergistic network.The ETS domain transcription factor ELK1 directs a critical component of growth signaling by the androgen receptor in prostate cancer cells Mash1 expression is induced in neuroendocrine prostate cancer upon the loss of Foxa2.Effects of manganese superoxide dismutase silencing on androgen receptor function and gene regulation: implications for castration-resistant prostate cancer

P2860

Q21202034-F03E9363-938E-4099-B52C-71C8D9BC34E8 Q27687896-CA5A480A-1EEA-4736-BC47-72976E4A6BA7 Q27990300-43B07612-A4D4-489D-A4AF-7C3B5617962F Q28116177-A239C05A-0E32-4958-B3AD-9F56ADA5D30B Q28116222-96DC67AC-861E-4FC9-85A3-024F7C52C740 Q28483533-88398E14-F126-486D-9CBA-C5C30FABFDA1 Q28547243-03B3F5B8-21F1-4705-8196-6CA19D1DFD4C Q30416201-D9D97635-A769-45E3-8CB2-05CAA328AF7B Q33280165-70D2F683-F6C1-43DE-B098-D630488354C6 Q33373567-286BD632-CC52-420B-B141-EBE6A36712E6 Q33455428-3F23B54D-AAA3-4792-BEE3-DBF6C7E54095 Q33488343-B4344299-0BE4-4571-93A7-0D8B75C67499 Q33592512-3060ACB9-1E4B-4C8E-B423-F867FA8E680C Q33728239-5DEED3E9-28F4-4F57-AF28-24316871A027 Q33735295-A930B0BC-8723-403E-A344-D299F63128A2 Q33798864-1F873FD9-9B1F-4588-A58C-C3D494E20A33 Q33835918-C357BBF6-84AA-4460-8ADC-A94228BEA8F8 Q33866927-A8B1C1CA-1782-402A-8FB7-87F1618175A1 Q33942107-E1A839A8-346E-4948-AC0C-D2E98535EA24 Q33974305-7A3ACBD7-F468-42FE-BC5D-51C74D2045AE Q33988757-8AA51529-E91B-4BE6-8E78-2144559CF328 Q34116435-1CFB83A6-7241-450B-BBDD-559EF226BA27 Q34324662-C75F9D8E-2760-4F6F-A500-59CFE8E69212 Q34412268-6FD83711-C1F7-4099-AD5D-33198459416B Q34558036-A6B0C829-8396-439B-B6C7-8AE5B94A34E7 Q34778972-A419C58F-7DA2-4B78-B13B-0D7132F18A7E Q35015135-7AFF6A0A-FA70-42F7-9DD7-6815D1C4B673 Q35082989-D61E8ABE-F873-4ADD-A91E-304138DF8D58 Q35109839-3E787E32-FF1C-4F21-8948-B73B707B52A5 Q35192163-E7BD5D6C-DA4F-4609-9DF0-2EE27BC9EDD4 Q35721689-9140C804-A4A7-4644-91C6-04B853D6B256 Q35963298-326BDDC7-CCD4-48B7-B248-BAB0B8104031 Q36172537-9C172C8D-6835-44C6-9184-CD07BC74D936 Q36277733-2A5CCC21-078B-47DD-979B-45B70B97A169 Q36294460-1D308A49-5C9C-4CAE-BD84-1D2A4633FD07 Q36611417-7D57D8C9-1AF3-4F39-ACBE-7FB40607E35D Q36685517-E8E6080D-5DF9-41BC-B594-24DF8AC700F1 Q36779605-AD3A74AC-863F-4BA2-A05E-7E4716CAC298 Q37021198-564B82A9-3C1D-47A5-81FE-395384A70E3A Q37162112-F015921D-8B9D-48E4-BA58-CC29A161B482

P2860

Molecular alterations in primary prostate cancer after androgen ablation therapy.

http://www.wikidata.org/entity/Q33224548

description

2005 nî lūn-bûn

@nan

2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Molecular alterations in primary prostate cancer after androgen ablation therapy.

@ast

Molecular alterations in primary prostate cancer after androgen ablation therapy.

@en

type

label

Molecular alterations in primary prostate cancer after androgen ablation therapy.

@ast

Molecular alterations in primary prostate cancer after androgen ablation therapy.

@en

prefLabel

Molecular alterations in primary prostate cancer after androgen ablation therapy.

@ast

Molecular alterations in primary prostate cancer after androgen ablation therapy.

@en

P1433

Q33224548-6628C791-F2CE-43DB-A489-9DF63CE31C55

P1476

Q33224548-78840B20-E85A-4981-8C7B-DF6DD80810DE

P2093

Q33224548-0142639A-5422-4BDC-B648-954CFB82C877

Q33224548-056BB44D-0EA4-4172-B436-D105E8DC3760

Q33224548-28B3ECA1-71F8-4892-A4C3-C3422F1B557D

Q33224548-3A4FAE58-AD85-4651-B43A-9D5CB5CC1F50

Q33224548-60AA7A6B-4EE9-4E52-88C8-58D6851460C2

Q33224548-677E40C1-557B-48AD-8DF4-8A57D782A8AA

Q33224548-77C77667-205D-4FA5-B477-DA63F982DE3D

Q33224548-A2D9AFE7-0307-4E47-8A36-2FAC1B7C10CB

Q33224548-A2F6412C-CBF6-4F5B-80A7-6C63FE2DD057

Q33224548-ADEE3A0E-153E-42DE-AADF-A07D18F069E2

P2860

Q33224548-026719DF-E1BB-45F6-9F20-E5CA84AE3082

Q33224548-02755B38-80AD-4FCF-8C43-EB66509398A9

Q33224548-06AACDFF-1943-4F8D-8EF3-F1DE452E218B

Q33224548-0A6D9FCA-A68A-47E7-A4BB-D9CC8A73B292

Q33224548-0C7B972D-A660-40CB-87AE-A7F258EFCB7D

Q33224548-1123A1D2-EF6B-4A4A-A5A8-A5B619BF65FB

Q33224548-19D53897-24E8-445B-9094-D5151376F3B7

Q33224548-1CF16588-708B-474F-8E57-DD4C16254664

Q33224548-1DAE5502-58A0-4E94-BD17-AEA9794B0A02

Q33224548-24A12BFF-976B-4743-8C23-1DA7B386CAF3

P304

Q33224548-067CB052-F4E0-4AA6-82B1-42EA6F1D11E1

P31

Q33224548-A648B0F0-127E-48F6-8387-D0F12E3A66E5

P356

Q33224548-55054E1D-F975-4E1F-AC10-C4688F0AF6E3

P407

Q33224548-B7C1390C-5673-49A3-97EA-28D6448FA6EB

P433

Q33224548-A47738DE-DE9F-495A-95A4-FBB40E5D1A3F

P478

Q33224548-19417209-9F2C-4AB7-A253-158226B5F3EA

P577

Q33224548-CA0B2399-752B-4A15-86E2-F8228BAE7CBB

P5875

Q33224548-CCF16039-7C96-4432-93BA-1C3D6AE60209

P698

Q33224548-2F5E4D44-75A5-4ABC-A89E-5E65C0122CF5

P932

Q33224548-15A9EF28-3731-4536-951E-CE206B1D2815

P356

1078-0432.CCR-05-0585

P1433

Clinical Cancer Research

P1476

Molecular alterations in primary prostate cancer after androgen ablation therapy.

@en

P2093

Alfredo Velasco

http://www.w3.org/2001/XMLSchema#string

Carolyn J M Best

http://www.w3.org/2001/XMLSchema#string

Douglas K Price

http://www.w3.org/2001/XMLSchema#string

Gadisetti V R Chandramouli

http://www.w3.org/2001/XMLSchema#string

Heidi S Erickson

http://www.w3.org/2001/XMLSchema#string

John W Gillespie

http://www.w3.org/2001/XMLSchema#string

Lauren Georgevich

http://www.w3.org/2001/XMLSchema#string

Mark A Perlmutter

http://www.w3.org/2001/XMLSchema#string

Michael A Tangrea

http://www.w3.org/2001/XMLSchema#string

Michael R Emmert-Buck

http://www.w3.org/2001/XMLSchema#string

P2860

In silico cloning of novel endothelial-specific genes

Identifying biological themes within lists of genes with EASE

Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells.

Optimization and evaluation of T7 based RNA linear amplification protocols for cDNA microarray analysis.

Differential gene expression by endothelial cells in distinct angiogenic states

Molecular determinants of resistance to antiandrogen therapy

Gadd45gamma is androgen-responsive and growth-inhibitory in prostate cancer cells

Association between gene expression profile and tumor invasion in oral squamous cell carcinoma

Laser capture microdissection

A molecular signature of metastasis in primary solid tumors

P304

6823-6834

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-05-0585

http://www.w3.org/2001/XMLSchema#string

P407

P433

19 Pt 1

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2005-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7561022

http://www.w3.org/2001/XMLSchema#string

P698

16203770

http://www.w3.org/2001/XMLSchema#string

P932

1432092

http://www.w3.org/2001/XMLSchema#string